Pharmaceutical

Risk adjusted net present value: What is the current valuation of Plus Therapeutics’s Rhenium (186Re) Obisbemeda?

Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeutics, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM).

Dec 13, 2024 - 06:00
Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeutics, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of ORIC Pharmaceu...

Next Article

Risk adjusted net present value: What is the current valuation of Eli Lilly and ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: CRISPR history, biotech struggles, & a big week for deals

Listen: CRISPR history, biotech struggles, & a big week...

Dec 7, 2023

Hisamitsu Pharmaceutical sees highest patent filings an...

Dec 10, 2023

Oral solid dosage manufacturing companies, equipment and market

Oral solid dosage manufacturing companies, equipment an...

May 11, 2024